中东和非洲人类胰岛素市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

市场按产品类型(基础或长效胰岛素、丸剂或速效胰岛素、传统人胰岛素、生物仿制胰岛素和组合胰岛素)和地理位置进行细分。

市场快照

Middle-East and Africa human insulin market Overview
Study Period: 2016-2027
Base Year: 2021
CAGR: 4.6 %
Middle-East and Africa human insulin market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

在预测期间(2020 - 2025 年),中东和非洲人胰岛素市场预计将以 4.6% 的复合年增长率增长。全世界有近 1 亿人需要胰岛素,包括所有 1 型糖尿病患者和 10-25% 的 2 型糖尿病患者。尽管胰岛素用于治疗糖尿病已有 90 多年的历史,但在全球范围内,今天需要胰岛素的人中有一半以上仍然负担不起,也无法获得。1 型糖尿病患者需要胰岛素治疗,治疗的重点是用胰岛素、饮食和生活习惯控制血糖水平,以预防并发症。

报告范围

中东和非洲人胰岛素市场涵盖以下几个方面:

By Product Type
Basal or Long-acting Insulins (Value and Volume, 2012 - 2025)
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast-acting Insulins (Value and Volume, 2012 - 2025)
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins (Value and Volume, 2012 - 2025)
Novolin/Actrapid/Insulatard
Humilin
Insuman
Combination Insulins (Value and Volume, 2012 - 2025)
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Soliqua/Suliqua (Insulin glargine/Lixisenatide)
Biosimilar Insulins (Value and Volume, 2012-2025)
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Geography
Middle-East and Africa
Saudi Arabia (Value and Volume, 2012 - 2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
Iran (Value and Volume, 2012 - 2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
Egypt (Value and Volume, 2012 - 2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
Oman (Value and Volume, 2012 - 2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
South Africa (Value and Volume, 2012 - 2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
Rest of Middle-East and Africa (Value and Volume, 2012 - 2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations

Report scope can be customized per your requirements. Click here.

主要市场趋势

预计糖尿病患病率的增加将在预测期内提振市场

中东和非洲的糖尿病患者人数在过去几年中急剧增加,原因包括该地区老年人口的增加以及由于不健康的饮食和缺乏身体活动导致的超重和肥胖人口的增加。由于糖尿病可能会增加心血管疾病的风险,因此需要通过定期寻求合适的治疗来对其进行妥善管理。根据世界卫生组织的数据,2019 年,中东和非洲约有 2200 万人患有糖尿病。根据埃及糖尿病协会的数据,2019 年,埃及有近 840 万人被诊断出患有糖尿病。埃及的 1 型糖尿病诊断率最高。据埃及糖尿病协会报道,在 14 岁以下的儿童中,约有十分之一的病例是 1 型糖尿病。

Middle-East and Africa human insulin market Key Trends

生物仿制药胰岛素占有重要的市场份额

与品牌胰岛素相比,生物仿制药胰岛素在中东和非洲地区非常受欢迎,因为它的成本较低。中东和非洲国家具有巨大的经济多样性。该地区的人均糖尿病支出较低,尽管该地区的一些国家已设法调整其医疗保健支出,以包括生物和生物仿制药疗法。中东和非洲国家政府正在认识到推动生物仿制药的重要性,以创造一个具有竞争力和可持续发展的生物仿制药市场。在政府举措的推动下,几家公司正在开发与参考甘精胰岛素高度相似的生物仿制药,在疗效、安全性、纯度和效力方面没有临床意义的差异。

Middle-East and Africa human insulin market Growth by Region

竞争格局

中东和非洲人胰岛素市场由诺和诺德、赛诺菲和礼来公司主导。然而,有许多本土企业,如 Biocon、Julphar、Sedico 和 Exir,它们占据了相当大的市场份额。例如,2019 年,领先的印度生物技术公司 Biocon 和荷兰注册成立的 Mylan 宣布推出 Semglee(注射用 100 IU/mL 的甘精胰岛素溶液,在 3mL 预填充笔中),这是制药公司下第一个可用的甘精胰岛素生物类似药。福利计划 (PBS)。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Dynamics

      1. 4.2.1 Market Drivers

      2. 4.2.2 Market Restraints

    3. 4.3 Industry Attractiveness - Porter's Five Forces Analysis

      1. 4.3.1 Bargaining Power of Suppliers

      2. 4.3.2 Bargaining Power of Consumers

      3. 4.3.3 Threat of New Entrants

      4. 4.3.4 Threat of Substitute Products and Services

      5. 4.3.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product Type

      1. 5.1.1 Basal or Long-acting Insulins (Value and Volume, 2012 - 2025)

        1. 5.1.1.1 Lantus (Insulin Glargine)

        2. 5.1.1.2 Levemir (Insulin Detemir)

        3. 5.1.1.3 Toujeo (Insulin Glargine)

        4. 5.1.1.4 Tresiba (Insulin Degludec)

        5. 5.1.1.5 Basaglar (Insulin Glargine)

      2. 5.1.2 Bolus or Fast-acting Insulins (Value and Volume, 2012 - 2025)

        1. 5.1.2.1 NovoRapid/Novolog (Insulin Aspart)

        2. 5.1.2.2 Humalog (Insulin Lispro)

        3. 5.1.2.3 Apidra (Insulin Glulisine)

      3. 5.1.3 Traditional Human Insulins (Value and Volume, 2012 - 2025)

        1. 5.1.3.1 Novolin/Actrapid/Insulatard

        2. 5.1.3.2 Humilin

        3. 5.1.3.3 Insuman

      4. 5.1.4 Combination Insulins (Value and Volume, 2012 - 2025)

        1. 5.1.4.1 NovoMix (Biphasic Insulin Aspart)

        2. 5.1.4.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

        3. 5.1.4.3 Xultophy (Insulin Degludec and Liraglutide)

        4. 5.1.4.4 Soliqua/Suliqua (Insulin glargine/Lixisenatide)

      5. 5.1.5 Biosimilar Insulins (Value and Volume, 2012-2025)

        1. 5.1.5.1 Insulin Glargine Biosimilars

        2. 5.1.5.2 Human Insulin Biosimilars

    2. 5.2 Geography

      1. 5.2.1 Middle-East and Africa

        1. 5.2.1.1 Saudi Arabia (Value and Volume, 2012 - 2025)

          1. 5.2.1.1.1 Basal or Long-acting Insulins

          2. 5.2.1.1.2 Bolus or Fast-acting Insulins

          3. 5.2.1.1.3 Traditional Human Insulins

          4. 5.2.1.1.4 Biosimilar Insulins

          5. 5.2.1.1.5 Insulin Combinations

        2. 5.2.1.2 Iran (Value and Volume, 2012 - 2025)

          1. 5.2.1.2.1 Basal or Long-acting Insulins

          2. 5.2.1.2.2 Bolus or Fast-acting Insulins

          3. 5.2.1.2.3 Traditional Human Insulins

          4. 5.2.1.2.4 Biosimilar Insulins

          5. 5.2.1.2.5 Insulin Combinations

        3. 5.2.1.3 Egypt (Value and Volume, 2012 - 2025)

          1. 5.2.1.3.1 Basal or Long-acting Insulins

          2. 5.2.1.3.2 Bolus or Fast-acting Insulins

          3. 5.2.1.3.3 Traditional Human Insulins

          4. 5.2.1.3.4 Biosimilar Insulins

          5. 5.2.1.3.5 Insulin Combinations

        4. 5.2.1.4 Oman (Value and Volume, 2012 - 2025)

          1. 5.2.1.4.1 Basal or Long-acting Insulins

          2. 5.2.1.4.2 Bolus or Fast-acting Insulins

          3. 5.2.1.4.3 Traditional Human Insulins

          4. 5.2.1.4.4 Biosimilar Insulins

          5. 5.2.1.4.5 Insulin Combinations

        5. 5.2.1.5 South Africa (Value and Volume, 2012 - 2025)

          1. 5.2.1.5.1 Basal or Long-acting Insulins

          2. 5.2.1.5.2 Bolus or Fast-acting Insulins

          3. 5.2.1.5.3 Traditional Human Insulins

          4. 5.2.1.5.4 Biosimilar Insulins

          5. 5.2.1.5.5 Insulin Combinations

        6. 5.2.1.6 Rest of Middle-East and Africa (Value and Volume, 2012 - 2025)

          1. 5.2.1.6.1 Basal or Long-acting Insulins

          2. 5.2.1.6.2 Bolus or Fast-acting Insulins

          3. 5.2.1.6.3 Traditional Human Insulins

          4. 5.2.1.6.4 Biosimilar Insulins

          5. 5.2.1.6.5 Insulin Combinations

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetes Population (2012 - 2025)

    2. 6.2 Type-2 Diabetes Population (2012 - 2025)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Novo Nordisk

        1. 7.1.1.1 Overview

        2. 7.1.1.2 Products and Strategies

        3. 7.1.1.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.1.4 Ratio Analysis (Five Years)

        5. 7.1.1.5 Strength and Stability Analysis (Five Years)

        6. 7.1.1.6 Recent Developments

      2. 7.1.2 Sanofi Aventis

        1. 7.1.2.1 Overview

        2. 7.1.2.2 Products and Strategies

        3. 7.1.2.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.2.4 Ratio Analysis (Five Years)

        5. 7.1.2.5 Strength and Stability Analysis (Five Years)

        6. 7.1.2.6 Recent Developments

      3. 7.1.3 Eli Lilly

        1. 7.1.3.1 Overview

        2. 7.1.3.2 Products and Strategies

        3. 7.1.3.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.3.4 Ratio Analysis (Five Years)

        5. 7.1.3.5 Strength and Stability Analysis (Five Years)

        6. 7.1.3.6 Recent Developments

      4. 7.1.4 Biocon

        1. 7.1.4.1 Overview

        2. 7.1.4.2 Products and Strategies

        3. 7.1.4.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.4.4 Ratio Analysis (Five Years)

        5. 7.1.4.5 Strength and Stability Analysis (Five Years)

        6. 7.1.4.6 Recent Developments

      5. 7.1.5 Pfizer

        1. 7.1.5.1 Overview

        2. 7.1.5.2 Products and Strategies

        3. 7.1.5.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.5.4 Ratio Analysis (Five Years)

        5. 7.1.5.5 Strength and Stability Analysis (Five Years)

        6. 7.1.5.6 Recent Developments

      6. 7.1.6 Wockhardt

        1. 7.1.6.1 Overview

        2. 7.1.6.2 Products and Strategies

        3. 7.1.6.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.6.4 Ratio Analysis (Five Years)

        5. 7.1.6.5 Strength and Stability Analysis (Five Years)

        6. 7.1.6.6 Recent Developments

      7. 7.1.7 Julphar

        1. 7.1.7.1 Overview

        2. 7.1.7.2 Products and Strategies

        3. 7.1.7.3 Recent Developments

      8. 7.1.8 Exir

        1. 7.1.8.1 Overview

        2. 7.1.8.2 Products and Strategies

        3. 7.1.8.3 Recent Developments

      9. 7.1.9 SEDICO

        1. 7.1.9.1 Overview

        2. 7.1.9.2 Products and Strategies

        3. 7.1.9.3 Recent Developments

    2. 7.2 Company Share Analysis

      1. 7.2.1 Novo Nordisk AS

      2. 7.2.2 Sanofi Aventis

      3. 7.2.3 Eli Lilly and Company

      4. 7.2.4 Other Companies

  8. 8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

  9. 9. 9. Detailed Analysis on WHO Prequalification for Insulin (Steps of Prequalification Process, Procedures and Fee Structure, Prequalification Guidelines, Prequalification Pipeline, and Others)

  10. 10. 10. Estimation Of prequalification Impact on the Insulin Market and Insulin Prices

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Middle-East and Africa Human Insulin Market market is studied from 2016 - 2027.

The Middle-East and Africa Human Insulin Market is growing at a CAGR of 4.6% over the next 5 years.

Novo Nordisk, Sanofi, Eli lilly, Wockhardt, Pfizer are the major companies operating in Middle-East and Africa Human Insulin Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!